Costa Viviana, PhD
Health Researcher - Omic Science Platform for Personalized Orthopedics
2009: Master Degree in Molecular and Cellular Medical Biotechnology at the University of Rome "Sapienza", with honors.
- 2013: Ph.D in Pasteuriane Science, University of Rome "La Sapienza"
- 2010: National qualification for the profession of Biologist, University of Viterbo "Tuscia", Faculty of Science, Viterbo, Italy.
- Dal 2020: Health Researcher at IOR, unit Omic Science Platform for Personalized Orthopedics (Surgical Sciences and Technologies)
- 2020: Health Researcher at IOR, unit Omic Science Platform for Personalized Orthopedics
- 2019-20: Health Researcher at IOR, Technological Platform for Tissue Engineering, Teranostics and Oncology
- 2018-21: In charge of the clinical protocol Bio.Pre.I.OA. developed in collaboration between the Technological Platform for Tissue Engineering, Teranostics, and Oncology and the Rizzoli Orthopedic Institute-Bagheria (PA Italy)
- 2016-19: Medical Biotechnologist at the Technological Platform for Tissue Engineering, Teranostics, and Oncology, IOR
- 2015-16: Contract Medical Biotechnologist for the PON01_01059 project - Technological Platform for Tissue Engineering, Teranostics, and Oncology
- 2013-14: Contract Medical Biotechnologist for the PON01_00829 project - Innovative Technology Platforms for Tissue Engineering
- 2012-13: Cenci Bolognetti Researcher (fellowship) for the Laboratory of Gene Expression and Experimental Hepatology of the National Institute for Infectious Diseases "L. Spallanzani", University "Sapienza", Rome
- 2008-09: 2009 Spinner Researcher (fellowship) for "Spinner 2010-2013 - CAPS-IT" (Spinner Ferrara 2009/2010 project- University of Ferrara), Ferrara (Italy).
English (level B1) according to the Common European Framework of Reference for Languages.
Excellent computer skills and competence of: Microsoft Office (Word, Excel, Power Point), graphics applications (AdobeIllustrator™, PhotoShop™, GraphPAD) and of Bioinformatical tools.
- Osteoporosis, osteoarthritis, osteosarcoma, bone metastases
- Regenerative medicine for bone and cartilage pathologies
- MiRNA and long non coding RNA involved in tumor progression and in bone regenerative process (physiological and pathological)
- Liquid biopsy from patients with osteosarcoma, multiple myeloma or bone metastases
- Biophysical treatments: low and high intensity ultrasound
- Nanovesicle engineering for degenerative and oncological orthopaedic diseases.